According to a new report published by MarkWide Research, titled, “Global Predictive and Presymptomatic Testing Market,” the global market for predictive and presymptomatic testing is expected to experience significant growth. These tests play a pivotal role in personalized healthcare by identifying genetic predispositions and potential health risks.
The report reveals that the global predictive and presymptomatic testing market is projected to witness a robust CAGR of 8.2% over the forecast period from 2023 to 2030. This growth is driven by the increasing adoption of precision medicine, advancements in genomics, and the growing awareness of proactive health management.
Key Findings from the Report:
- Personalized Healthcare: Predictive and presymptomatic testing enable personalized healthcare strategies by identifying genetic markers associated with diseases and conditions.
- Genomic Advancements: Advances in genomics and genetic sequencing technologies have expanded the scope and accuracy of predictive testing.
- Cancer Risk Assessment: These tests are instrumental in assessing the genetic risk of developing cancer, allowing for early intervention and prevention.
- Healthcare Decision-Making: Information from predictive testing empowers individuals and healthcare providers to make informed decisions about treatment and prevention.
- Data Security and Privacy: Ensuring the security and privacy of genetic data is a critical consideration in the industry.
The report indicates that the global predictive and presymptomatic testing market is currently valued at $6.8 billion in 2023 and is projected to reach $12.7 billion by 2030, with a CAGR of 8.2% during the forecast period. North America and Europe are expected to be key regions for market growth.
Key players in the global predictive and presymptomatic testing market include Myriad Genetics, Inc., 23andMe, Inc., and Quest Diagnostics Incorporated. These companies specialize in offering genetic testing services and solutions.
The global predictive and presymptomatic testing market is set for significant growth, driven by the increasing importance of personalized healthcare and genetic insights. With a projected CAGR of 8.2% by 2030, this market offers opportunities for companies to contribute to the future of proactive health management.